TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14365/4
Browse
4 results
Search Results
Article Citation - Scopus: 1Course of Treatment of Chronic Bleeding and Anemia with Systemic Bevacizumab Treatment in Hereditary Hemorrhagic Telangiectasia: A Retrospective Cohort(Türkiye Klinikleri, 2023) Durak, Emine; Ugur, Mehmet Can; Gediz, FusunAmaç: Kalıtsal hemorajik telenjiyektazi (HHT), anormal anjiyo- geneze neden olan otozomal dominant bir hastal ıktır. Son y ıllarda, özel- likle şiddetli HHT formlarının tedavisi için hedefe yönelik tedavilere olan ilgi artmaktadır. Bu tedavi seçeneklerinden biri de vasküler endotelyal bü- yüme faktörü inhibitörü bevasizumabtır. Bu çalışmanın amacı, HHT tanısı alan hastalarda sistemik bevasizumab kullanımının kronik kanama seyri ve anemi tedavisindeki etkisini ara ştırmaktır. Gereç ve Yöntemler: Bevasi- zumab kullanan hastaların tedavi yanıtı ve yan etkileri retrospektif olarak değerlendirildi. Bulgular: Hastaların yaş ortalaması 51,5 yıl idi. Ortalama tedavi süresi 15,4 (4-25 ay) aydı. Tüm hastalara 2 hafta arayla ilk 4 doz 5 mg/kg intravenöz bevasizumab uygulandı. Bevasizumab idamesi 5 mg/kg dozunda aylık periyotlarla devam etti. Bevasizumab tedavisi ile hemoglo- bin değerlerinde artış, epistaksis şiddet skorunda parenteral demir ve erit- rosit transfüzyon gereksiniminde azalma sağlandı. Gözlenen yan etkiler, 1 hastada alerjik döküntü ve 1 hastada artralji idi. Yan etkiler nedeniyle hiç- bir hastada tedavinin kesilmesi gerekmedi. Sonuç: Bevasizumab, kontrol edilmediği takdirde ölümcül olabilen HHT’de umut verici bir tedavi seçe- neğidir. Bununla birlikte, tedavi protokolleri ve advers olayların yönetimi konusunda global konsensus sağlamak için daha kapsamlı çalışmalara ih- tiyaç vardır.Article Knowledge, Attitudes, and Opinions of Hepatitis B Virus Carrier Male Patients About the Disease(Doc Design Informatics Co Ltd, 2022-09-28) Digrak, Ebru; Tezel, AyferObjectives: The study was conducted to evaluate the knowledge, attitudes, and opinions of male patients infected with the hepatitis B virus about their disease. Methods: This descriptive study was conducted in a military hospital in Ankara between July 2016 - July 2017. The study population consisted of 244 male patients admitted to the Infectious Diseases Clinic of the hospital within one year. No sample selection was made, and 208 patients accepted to participate were included in the study. The research data were collected by a questionnaire form consisting of 28 questions prepared by the researchers in line with the literature. For statistical analysis, IBM SPSS Statistics for Windows. Version 22.0 program was used. Results: Of the patients, 86.5% were single, 50% were primary school graduates, 65.4% were self-employed, and their mean age was 22.67 +/- 2.9. According to the data, 53.4% of the patients were HBeAg-negative, and 46.6% were HBeAg-positive chronic hepatitis B patients. Healthcare personnel was the information source for 51.9% of the patients, and 80.8% felt the need to get more information about their disease. 88.4% of the patients stated that hepatitis B disease could be transmitted through the bloodstream, and 80.7% of them stated that being vaccinated prevented them from being sick. 86.5% of the patients stated that the purpose of the treatment of hepatitis B disease was to prevent the progression of the disease. Conclusions: According to the study's results, we determined that the patients' knowledge and attitudes about their diseases were insufficient.Article Citation - Scopus: 3Clinical Impact of Hepatitis C Virus Genomic Variations(Ankara Microbiology Society, 2015-10-08) Ergünay K.; Abacioglu H.; Ergünay, Koray; Abacioglu, HakanHepatitis C virus (HCV) is a globally-dispersed agent of chronic hepatitis with a significant public health threat, affecting over 110 million individuals throughout the world. The increased risk for chronicity after exposure and the lack of a protective vaccine make HCV is a leading infectious cause of cirrhosis, liver failure requiring transplantation and hepatocellular carcinoma. The replicative process and infection dynamics in the host enable HCV to generate an array of closely-related but non-identical genetic variants known as quasispecies in the infected individuals. Pathogenesis and outcome in HCV infections are directly affected by the virus genetic heterogeneity, reflected as the emergence of quasispecies in infected individuals. The evolution of these highly-diverse viral populations in the host directly influences the disease course, via providing a pool of variants capable of resuming viral replication under extrinsic and/or intrinsic selective pressures. Viral quasispecies go through several alterations during the course of the infection, and provide a background for the selection of escape mutants from the host humoral and cell-mediated immune responses and antiviral treatment. Supported by the robust next generation sequencing techniques, recent studies have provided significant insights on the genomic diversity and progression as well as on the origin and the epidemiology of HCV. This review provides an overview of the mechanisms of HCV genetic variability, and the interactions with the host, that affects clinical disease, covering viral and host determinants of humoral and cell-mediated immune responses, alterations during the early and late stages of the infection and disease progression leading to chronicity. In addition, current findings in virus evolution and epidemiology were briefly interpreted from the inter-species and population perspectives. The impact of viral genomic heterogeneity on antiviral treatment in the era of direct-acting agents is also discussed, along with an overview of current methods employed for the characterization of viral diversity.Article Citation - WoS: 15Citation - Scopus: 17Identification of the Nucleotide Substitutions in 62 Sars-Cov Sequences From Turkey(Tubitak Scientific & Technical Research Council Turkey, 2020-06-21) Demir, Ayse Banu; Benvenuto, Domenico; Abacioglu, Hakan; Angeletti, Silvia; Ciccozzi, MassimoA previously unknown coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been shown to cause coronavirus disease 2019 (COVID-19) pandemic. The first case of COVID-19 in Turkey has been declared in March 11th, 2020 and from there on, more than 150,000 people in the country have been diagnosed with the disease. In this study, 62 viral sequences from Turkey, which have been uploaded to GISAID database, were analyzed by means of their nucleotide substitutions in comparison to the reference SARS-CoV-2 genome from Wuhan. Our results indicate that the viral isolates from Turkey harbor some common mutations with the viral strains from Europe, Oceania, North America and Asia. When the mutations were evaluated, C3037T, C14408T and A23403G were found to be the most common nucleotide substitutions among the viral isolates in Turkey, which are mostly seen as linked mutations and are part of a haplotype observed high in Europe.